MX2016005614A - Cuerpos de inclusion para el suministro transdermico de agentes terapeuticos y cosmeticos. - Google Patents
Cuerpos de inclusion para el suministro transdermico de agentes terapeuticos y cosmeticos.Info
- Publication number
- MX2016005614A MX2016005614A MX2016005614A MX2016005614A MX2016005614A MX 2016005614 A MX2016005614 A MX 2016005614A MX 2016005614 A MX2016005614 A MX 2016005614A MX 2016005614 A MX2016005614 A MX 2016005614A MX 2016005614 A MX2016005614 A MX 2016005614A
- Authority
- MX
- Mexico
- Prior art keywords
- therapeutic
- cosmetic agents
- transdermal delivery
- inclusion bodies
- agents
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/02—Cosmetics or similar toiletry preparations characterised by special physical form
- A61K8/0216—Solid or semisolid forms
- A61K8/022—Powders; Compacted Powders
- A61K8/0225—Granulated powders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/43—Enzymes; Proenzymes; Derivatives thereof
- A61K38/44—Oxidoreductases (1)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/1767—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from invertebrates
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/18—Growth factors; Growth regulators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/18—Growth factors; Growth regulators
- A61K38/1808—Epidermal growth factor [EGF] urogastrone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/18—Growth factors; Growth regulators
- A61K38/1858—Platelet-derived growth factor [PDGF]
- A61K38/1866—Vascular endothelial growth factor [VEGF]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/19—Cytokines; Lymphokines; Interferons
- A61K38/20—Interleukins [IL]
- A61K38/2066—IL-10
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/02—Cosmetics or similar toiletry preparations characterised by special physical form
- A61K8/0208—Tissues; Wipes; Patches
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/02—Cosmetics or similar toiletry preparations characterised by special physical form
- A61K8/0241—Containing particulates characterized by their shape and/or structure
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
- A61K8/64—Proteins; Peptides; Derivatives or degradation products thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
- A61K8/64—Proteins; Peptides; Derivatives or degradation products thereof
- A61K8/66—Enzymes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0014—Skin, i.e. galenical aspects of topical compositions
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/70—Web, sheet or filament bases ; Films; Fibres of the matrix type containing drug
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/02—Stomatological preparations, e.g. drugs for caries, aphtae, periodontitis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
- A61P15/02—Drugs for genital or sexual disorders; Contraceptives for disorders of the vagina
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/04—Antipruritics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/06—Antipsoriatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/10—Anti-acne agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/12—Keratolytics, e.g. wart or anti-corn preparations
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/16—Emollients or protectives, e.g. against radiation
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/10—Antimycotics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
- A61Q19/00—Preparations for care of the skin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
- A61Q19/00—Preparations for care of the skin
- A61Q19/007—Preparations for dry skin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
- A61Q19/00—Preparations for care of the skin
- A61Q19/06—Preparations for care of the skin for countering cellulitis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
- A61Q19/00—Preparations for care of the skin
- A61Q19/08—Anti-ageing preparations
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
- A61Q5/00—Preparations for care of the hair
- A61Q5/006—Antidandruff preparations
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2800/00—Properties of cosmetic compositions or active ingredients thereof or formulation aids used therein and process related aspects
- A61K2800/40—Chemical, physico-chemical or functional or structural properties of particular ingredients
- A61K2800/41—Particular ingredients further characterized by their size
- A61K2800/413—Nanosized, i.e. having sizes below 100 nm
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2800/00—Properties of cosmetic compositions or active ingredients thereof or formulation aids used therein and process related aspects
- A61K2800/40—Chemical, physico-chemical or functional or structural properties of particular ingredients
- A61K2800/60—Particulates further characterized by their structure or composition
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Y—ENZYMES
- C12Y111/00—Oxidoreductases acting on a peroxide as acceptor (1.11)
- C12Y111/01—Peroxidases (1.11.1)
- C12Y111/01006—Catalase (1.11.1.6)
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Epidemiology (AREA)
- Gastroenterology & Hepatology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Immunology (AREA)
- Dermatology (AREA)
- Zoology (AREA)
- Organic Chemistry (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Birds (AREA)
- Vascular Medicine (AREA)
- Communicable Diseases (AREA)
- Oncology (AREA)
- Biomedical Technology (AREA)
- Gerontology & Geriatric Medicine (AREA)
- Virology (AREA)
- Endocrinology (AREA)
- Reproductive Health (AREA)
- Gynecology & Obstetrics (AREA)
- Toxicology (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Medicinal Preparation (AREA)
- Cosmetics (AREA)
Abstract
La presente invención se relaciona con métodos, composiciones y dispositivos para el suministro transdérmico de agentes terapéuticos y agentes cosméticos en forma de cuerpos de inclusión, estos cuerpos de inclusión. Estos cuerpos de inclusión pueden suministrar agentes terapéuticos y cosméticos a través de la barrera de la piel y llegar a lugares profundos en la piel. Las composiciones descritas pueden usarse para tratar enfermedades y afecciones de la piel.
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US201361898698P | 2013-11-01 | 2013-11-01 | |
PCT/IB2014/003004 WO2015063613A2 (en) | 2013-11-01 | 2014-10-31 | Inclusion bodies for transdermal delivery of therapeutic and cosmetic agents |
Publications (1)
Publication Number | Publication Date |
---|---|
MX2016005614A true MX2016005614A (es) | 2016-12-09 |
Family
ID=52474023
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
MX2016005614A MX2016005614A (es) | 2013-11-01 | 2014-10-31 | Cuerpos de inclusion para el suministro transdermico de agentes terapeuticos y cosmeticos. |
Country Status (9)
Country | Link |
---|---|
US (1) | US20160250298A1 (es) |
EP (1) | EP3062889A2 (es) |
JP (1) | JP2016535770A (es) |
KR (1) | KR20160083884A (es) |
CN (1) | CN105813695A (es) |
CA (1) | CA2928526A1 (es) |
MX (1) | MX2016005614A (es) |
RU (1) | RU2016117275A (es) |
WO (1) | WO2015063613A2 (es) |
Families Citing this family (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
KR101636846B1 (ko) | 2016-06-08 | 2016-07-07 | (주)넥스젠바이오텍 | 피부 세포 증식 및 항산화 효과가 증가한 보툴리눔 톡신-인간상피세포성장인자 융합단백질 및 이를 유효성분으로 함유하는 피부 재생 및 주름 개선용 화장료 조성물 |
DE102017107348B4 (de) | 2017-04-05 | 2019-03-14 | Olympus Soft Imaging Solutions Gmbh | Verfahren zur zytometrischen Analyse von Zellproben |
KR101951283B1 (ko) * | 2017-11-13 | 2019-02-22 | 양미경 | 탈모의 예방 또는 치료용, 또는 발모 또는 육모 촉진용 약학 또는 화장료 조성물 |
CN112272775A (zh) * | 2018-06-04 | 2021-01-26 | 雅芳产品公司 | 用于鉴定和治疗衰老皮肤和皮肤病症的蛋白生物标志物 |
Family Cites Families (77)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US3755560A (en) | 1971-06-30 | 1973-08-28 | Dow Chemical Co | Nongreasy cosmetic lotions |
LU71110A1 (es) | 1974-10-15 | 1976-11-11 | ||
ZA811368B (en) | 1980-03-24 | 1982-04-28 | Genentech Inc | Bacterial polypedtide expression employing tryptophan promoter-operator |
US4421769A (en) | 1981-09-29 | 1983-12-20 | The Procter & Gamble Company | Skin conditioning composition |
US4511503A (en) | 1982-12-22 | 1985-04-16 | Genentech, Inc. | Purification and activity assurance of precipitated heterologous proteins |
JPS633791A (ja) | 1986-06-25 | 1988-01-08 | Hitachi Ltd | プラスミド組換え体 |
JPS63202387A (ja) | 1987-02-18 | 1988-08-22 | Earth Chem Corp Ltd | Dna配列、これを含むベクタ−、該ベクタ−を保有する宿主細胞及びポリペプチドの製造法 |
US5034375A (en) | 1988-08-10 | 1991-07-23 | Institute Of Molecular Biology, Inc. | Process of wound healing using PDGF and EGF |
US5102789A (en) | 1989-03-15 | 1992-04-07 | The Salk Institute Biotechnology/Industrial Associates, Inc. | Production of epideramal growth factor in pichia pastoris yeast cells |
US5231012A (en) | 1989-06-28 | 1993-07-27 | Schering Corporation | Nucleic acids encoding cytokine synthesis inhibitory factor (interleukin-10) |
US5183805A (en) | 1990-08-13 | 1993-02-02 | Board Of Regents, The University Of Texas System | Bioactive egf peptides for promotion of tissue regeneration and cancer therapy |
US5145644A (en) | 1990-12-20 | 1992-09-08 | Allergan, Inc. | Hydrogen peroxide destroying compositions and methods of making and using same |
IE68836B1 (en) | 1991-01-16 | 1996-07-10 | Schering Corp | Use of interleukin-10 in adoptive immunotherapy of cancer |
AU2489992A (en) | 1991-08-16 | 1993-03-16 | Chiron Corporation | Muteins of epidermal growth factor exhibiting enhanced binding at low ph |
US5288931A (en) | 1991-12-06 | 1994-02-22 | Genentech, Inc. | Method for refolding insoluble, misfolded insulin-like growth factor-I into an active conformation |
US5665345A (en) | 1993-05-24 | 1997-09-09 | The United States Of America As Represented By The Department Of Health And Human Services | Methods of inhibiting viral replication using IL-10 |
SK153295A3 (en) | 1993-06-29 | 1996-11-06 | Chiron Corp | A truncated keratinocyte growth factor (kgf) having increased biological activity |
US6306829B1 (en) | 1995-12-08 | 2001-10-23 | Hybridon, Inc. | Modified VEGF oligonucleotides for treatment of skin disorders |
US6203803B1 (en) | 1994-12-14 | 2001-03-20 | Societe L'oreal S.A. | Use of a substance P antagonist in a cosmetic composition, and the composition thus obtained |
AU712606B2 (en) | 1995-08-09 | 1999-11-11 | Schering Corporation | Combined use of interleukin-10 and cyclosporin for immunosuppression therapy |
JPH11513405A (ja) | 1995-10-11 | 1999-11-16 | カイロン コーポレイション | 創傷治癒のためのpdgf、kgf、igf、およびigfbpの配合物 |
US5994306A (en) | 1995-11-22 | 1999-11-30 | Intrabiotics Pharmaceuticals, Inc. | Fine-tuned protegrins |
US5837265A (en) | 1996-03-08 | 1998-11-17 | The Regents Of The University Of California | Chemically-modified clostridiatoxin with improved properties |
US6169074B1 (en) | 1996-03-18 | 2001-01-02 | The Regents Of The University Of California | Peptide inhibitors of neurotransmitter secretion by neuronal cells |
US5753218A (en) | 1996-05-03 | 1998-05-19 | Schering Corporation | Method for treating inflammation |
ES2212121T3 (es) | 1996-08-13 | 2004-07-16 | Human Genome Sciences, Inc. | Mutantes de factor-2 de crecimiento queranocitico (kgf-2 o factor -12 de crecimiento fibroblastico, fgf-12). |
US6503881B2 (en) | 1996-08-21 | 2003-01-07 | Micrologix Biotech Inc. | Compositions and methods for treating infections using cationic peptides alone or in combination with antibiotics |
DK1012186T3 (da) | 1996-12-06 | 2002-11-04 | Amgen Inc | Keratinocyt-vækstfaktorer og anvendelser deraf |
ES2247676T3 (es) | 1997-01-07 | 2006-03-01 | Amylin Pharmaceuticals, Inc. | Uso de las exendinas y de los agonistas de las mismas para la reduccion de la ingesta alimenticia. |
CN1252808A (zh) | 1997-02-20 | 2000-05-10 | 耶达研究及发展有限公司 | 抗病原合成肽及包含该肽类的组合物 |
US6309656B1 (en) | 1998-11-27 | 2001-10-30 | Peter T. Pugliese | Cosmetic and skin protective compositions |
ES2160485B1 (es) | 1999-04-23 | 2002-05-16 | Lipotec Sa | Peptidos inhibidores de la exocitosis neuronal, composiciones cosmeticas y farmaceuticas que los contienen. |
US7307161B1 (en) | 1999-04-28 | 2007-12-11 | Genetics Institute, Llc | Human Gil-19/AE289 polynucleotides |
US6544504B1 (en) | 1999-07-28 | 2003-04-08 | Schering Corporation | Combined use of interleukin 10 and methotrexate for immuno-modulatory therapy |
JP2001186862A (ja) * | 1999-10-19 | 2001-07-10 | Makoto Hiuga | 粉末状アウレオバシジウム培養液組成物及びその製造方法並びにその組成物を用いた粉末混合物 |
US20060014684A1 (en) | 2000-03-03 | 2006-01-19 | University Technologies International Inc. | Novel uses of EGF |
AU2001247600A1 (en) | 2000-03-31 | 2001-10-15 | The General Hospital Corporation | Methods of modulating hair growth |
US7052686B2 (en) | 2000-09-29 | 2006-05-30 | Schering Corporation | Pegylated interleukin-10 |
CA2437270A1 (en) | 2001-02-06 | 2002-08-15 | Merck Patent Gesellschaft Mit Beschraenkter Haftung | Modified keratinocyte growth factor (kgf) with reduced immunogenicity |
US6875744B2 (en) | 2001-03-28 | 2005-04-05 | Helix Biomedix, Inc. | Short bioactive peptides |
ES2181592B1 (es) | 2001-06-14 | 2003-11-01 | Lipotec Sa | Uso de glicoproteina para el tratamiento y re-epitelizacion de heridas |
WO2003008443A2 (en) | 2001-07-19 | 2003-01-30 | Nymox Corporation | Peptides effective in the treatment of tumors and other conditions requiring the removal or destruction of cells |
WO2003016505A2 (en) | 2001-08-21 | 2003-02-27 | Chiron Corporation | Kgf polypeptide compositions |
JP2003116912A (ja) * | 2001-10-15 | 2003-04-22 | Kao Corp | 吸収性物品 |
US6872401B2 (en) | 2002-03-28 | 2005-03-29 | L'oreal | Cosmetic/dermatological compositions comprising a tetrahydrocurcuminoid and an amide oil |
SI21273A (sl) * | 2002-07-31 | 2004-02-29 | LEK farmacevtska dru�ba d.d. | Priprava inkluzijskih teles z visokim deležem pravilno zvitega prekurzorja heterolognega proteina |
US20050043235A1 (en) | 2003-06-12 | 2005-02-24 | Kari Alitalo | Use of VEGF-C or VEGF-D in reconstructive surgery |
CA2529863A1 (en) | 2003-06-17 | 2004-12-23 | Vib Vzw | Peptide combos and their uses |
US20050226839A1 (en) | 2003-09-08 | 2005-10-13 | Xueying Huang | Pepetide-based body surface reagents for personal care |
WO2005046709A2 (en) | 2003-11-06 | 2005-05-26 | Genencor International, Inc. | Tgf - beta binding and supported peptides |
ES2293753B1 (es) | 2004-04-28 | 2009-03-16 | Lipotec, S.A. | Uso de peptidos xikvav en preparacion de composiciones cosmeticas para mejorar la firmeza de la piel mediante el aumento de la adhesion celular. |
ES2261036B1 (es) | 2004-10-05 | 2007-12-16 | Lipotec, S.A. | Peptidos sinteticos que disminuyen o eliminan las bolsas formadas bajo el contorno inferior de los ojos y su uso en composiciones cosmeticas o dermofarmaceuticas. |
BRPI0517917B1 (pt) | 2004-11-02 | 2020-11-10 | Dsm Ip Assets B.V. | compostos, sais de adição de ácido, método para preparar os compostos, uso de compostos, composição topicamente aplicável, e, método para o tratamento de rugas de expressão e/ou relacionadas com a idade em pele humana |
ES2259928B1 (es) | 2005-04-08 | 2007-11-01 | Lipotec, S.A. | Composicion cosmetica o dermofarmaceutica que comprende peptidos derivados de encefalinas para reducir y/o eliminar arrugas faciales. |
WO2006138468A2 (en) | 2005-06-17 | 2006-12-28 | Genentech, Inc. | Use of vegf for wound healing |
US20060293227A1 (en) | 2005-06-24 | 2006-12-28 | Bhatnagar Rajendra S | Cosmetic compositions and methods using transforming growth factor-beta mimics |
US20070099889A1 (en) * | 2005-07-08 | 2007-05-03 | Paulette Royt | Use of pseudan and pseudan inclusion bodies |
TW200732347A (en) | 2005-10-06 | 2007-09-01 | Trophogen Inc | VEGF analogs and methods of use |
US8318659B2 (en) | 2005-11-15 | 2012-11-27 | E I Du Pont De Nemours And Company | Peptide-based organic sunscreens |
WO2007065464A1 (en) | 2005-12-09 | 2007-06-14 | Stichting Katholieke Universiteit | Epidermal growth factor (egf) derivatives with selectable selectivity for the erb receptor family |
EP2172210A1 (en) | 2005-12-23 | 2010-04-07 | Partnership&Corp. Technology Transfer | Synthetic peptides for use as inhibitors of neurotransmitter secretion |
US20080027005A1 (en) | 2006-07-31 | 2008-01-31 | Paul Averback | Peptides effective in the treatment of tumors and other conditions requiring the removal or destruction of cells |
ES2322882B1 (es) | 2006-10-25 | 2010-04-22 | Lipotec Sa | Peptidos inhibidores de la exocitosis neuronal. |
US9340601B2 (en) | 2007-03-01 | 2016-05-17 | The Board Of Trustees Of The Leland Stanford Junior University | Splice variants of the EGF receptor |
US20080234194A1 (en) | 2007-03-20 | 2008-09-25 | Harold Brem | Growth factor mediated cosmeceuticals and use thereof to enhance skin quality |
US8097581B2 (en) | 2007-05-10 | 2012-01-17 | Grant Industries Inc. | Anti-wrinkle cosmetic composition |
BRPI0705059B1 (pt) | 2007-06-28 | 2016-05-31 | Univ Rio De Janeiro | hidrolisados de queratina, processo para sua produção e composições cosméticas contendo os mesmos |
JP2010539125A (ja) * | 2007-09-13 | 2010-12-16 | ビーエーエスエフ ソシエタス・ヨーロピア | 浸透増強剤としてのハイドロフォビンポリペプチドの使用 |
US20090143295A1 (en) | 2007-11-30 | 2009-06-04 | E. I. Du Pont De Nemours And Company | Peptide-based antiacne reagents |
ES2342754B1 (es) | 2008-10-03 | 2011-05-11 | Lipotec, S.A. | Peptidos utiles en el tratamiento y/o cuidado de la piel, mucosas, cuero cabelludo y/o cabello y su uso en composiciones cosmeticas o farmaceuticas. |
ES2352489B1 (es) | 2008-12-30 | 2012-01-04 | CONSEJO SUPERIOR DE INVESTIGACIONES CIENTÍFICAS (Titular al 41%) | Cuerpos de inclusión, celulas bacterianas y composiciones que los contienen y sus usos. |
WO2010118880A1 (en) | 2009-04-17 | 2010-10-21 | Lipotec S.A. | Peptides used in the treatment and/or care of the skin and/or hair and their use in cosmetic or pharmaceutical compositions |
EP2251025A1 (en) * | 2009-05-12 | 2010-11-17 | Universitat Autònoma De Barcelona | Use of inclusion bodies as therapeutic agents |
JP5782439B2 (ja) | 2009-07-24 | 2015-09-24 | リポテック, エセ.ア.Lipotec, S.A. | 筋肉収縮を抑制する化合物 |
US20110305735A1 (en) | 2010-06-09 | 2011-12-15 | Lipotec, S.A. | Skin antiaging treatment |
EP2820033A4 (en) | 2012-02-29 | 2015-01-07 | Ambrx Inc | INTERLEUKIN 10 POLYPEPTIDE CONJUGATES AND ITS USES |
PE20150645A1 (es) | 2012-08-08 | 2015-05-11 | Roche Glycart Ag | Proteinas de fusion de interleuquina 10 y usos de las mismas |
-
2014
- 2014-10-31 KR KR1020167013990A patent/KR20160083884A/ko not_active Application Discontinuation
- 2014-10-31 EP EP14837036.4A patent/EP3062889A2/en not_active Withdrawn
- 2014-10-31 CA CA2928526A patent/CA2928526A1/en not_active Abandoned
- 2014-10-31 CN CN201480067777.8A patent/CN105813695A/zh active Pending
- 2014-10-31 RU RU2016117275A patent/RU2016117275A/ru unknown
- 2014-10-31 WO PCT/IB2014/003004 patent/WO2015063613A2/en active Application Filing
- 2014-10-31 JP JP2016551086A patent/JP2016535770A/ja active Pending
- 2014-10-31 MX MX2016005614A patent/MX2016005614A/es unknown
- 2014-10-31 US US15/033,492 patent/US20160250298A1/en not_active Abandoned
Also Published As
Publication number | Publication date |
---|---|
RU2016117275A (ru) | 2017-12-04 |
CN105813695A (zh) | 2016-07-27 |
US20160250298A1 (en) | 2016-09-01 |
WO2015063613A3 (en) | 2015-08-20 |
CA2928526A1 (en) | 2015-05-07 |
EP3062889A2 (en) | 2016-09-07 |
WO2015063613A2 (en) | 2015-05-07 |
JP2016535770A (ja) | 2016-11-17 |
KR20160083884A (ko) | 2016-07-12 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
PH12017500070A1 (en) | Methods of treating cancer using tigit inhibitors and anti-cancer agents | |
PH12016501139A1 (en) | Bicyclic heterocycle compounds and their uses in therapy | |
MX2021013830A (es) | Inhibidores de ezh2 para tratar linfomas. | |
MX2016007351A (es) | Terapia de combinacion para tratar cancer. | |
MX2019010601A (es) | Terapia de combinacion para tratar cancer. | |
NZ630805A (en) | Pharmaceutical combinations comprising a thionucleotide analog | |
CL2015000699A1 (es) | Métodos para tratamiento de cáncer. | |
EP4349414A3 (en) | Methods and formulations for transdermal administration | |
WO2015009726A3 (en) | Medical uses of cd38 agonists | |
MX2015010791A (es) | Metodos para tratar el cancer y prevenir la resistencia a farmacos. | |
PH12016502352A1 (en) | Pharmaceutical composition | |
TW201613578A (en) | Pharmaceutical combinations | |
MX2015010296A (es) | Tratamiento de formas progresivas de esclerosis multiple con laquinimod. | |
MX363543B (es) | Composicion farmaceutica que comprende compuesto de diaminocarboxamida heterociclica como ingrediente activo. | |
PH12018502161A1 (en) | Methods of treatment for cholestatic and fibrotic diseases | |
MX2016008150A (es) | Formulaciones de berberina y usos de las mismas. | |
MX2020009966A (es) | Formas de dosificacion y usos terapeuticos de la l-4-cloro quinurenina. | |
MX2018000262A (es) | Usos terapeuticos de formulaciones de berberina. | |
MX2016005614A (es) | Cuerpos de inclusion para el suministro transdermico de agentes terapeuticos y cosmeticos. | |
MX2020001428A (es) | Composiciones de grapiprant y metodos para usar las mismas. | |
PH12018500450A1 (en) | Immunity enhancing agent for cancer by allergin-1 antagonist | |
MX2017013666A (es) | Terapia de combinacion de agente anti-fuctactico y agente de inmunoterapia y composiciones para el tratamiento de cancer. | |
MX2018015240A (es) | Composiciones que comprenden timolol y su uso en el tratamiento de rosacea mediante administracion topica. | |
MX2017013668A (es) | Terapia de combinacion de agente anti-fuctactico y agente anti-cancer y composiciones para el tratamiento de cancer. | |
NZ725354A (en) | Transdermal formulations of pergolide and uses thereof |